Ultragenyx Pharmaceutical (RARE)

Executive Summary

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. The company has three approved products—Crysvita, Dojolvi, and Mepsevii—and a pipeline of 61 drug candidates spanning metabolic, neuromuscular, and endocrine disorders. Key late-stage assets include GTX-102 for Angelman syndrome (Phase 3, NCT06617429) and setrusumab for osteogenesis imperfecta (Phase 2/3, NCT05125809), both of which have the potential to address significant unmet needs. Ultragenyx's strategy emphasizes first-in-class or best-in-class treatments, leveraging its rare disease expertise and global commercial infrastructure. However, the company faces typical biotech risks, including clinical trial outcomes and regulatory hurdles, which are reflected in its moderate conviction score.

Upcoming Catalysts (preview)

• Q4 2026GTX-102 Phase 3 Interim Data in Angelman Syndrome60% success
• H1 2027Setrusumab Phase 2/3 Top-Line Results in Osteogenesis Imperfecta65% success
• H2 2027Potential Regulatory Filing for Setrusumab in OI50% success